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There is increasing evidence that the progression
of atherosclerosis to more clinically severe levels as
well as acute atherothrombotic complications such
as myocardial infarction and stroke may be related to
disorders of the host coagulation system.1-3
Impairment of patients’ coagulation dynamics may
occur due to an increase in procoagulant factors
such as fibrinogen or factor VIII,4 or a significant
decrease in endogenous fibrinolytic activity.1,2,4
Early studies observed that increased blood viscosity
and elevated fibrinogen levels were associated with
higher risks of coronary artery disease and recurrent
myocardial infarction (MI).5,6 More recent studies
have noted elevated levels of plasminogen activator
inhibitor-1 (PAI-1) activity in patients with recur-
rent MI,1 in those who develop restenosis after bal-
loon angioplasty,7 and in patients who suffer a
stroke.3 Because PAI-1 is the primary inhibitor of
endogenous fibrinolytic activity, this suggests that a
reduction in the host fibrinolytic system may medi-
ate the progression or complications of atherosclero-
sis in such cases. Other studies have demonstrated
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high levels of the tissue plasminogen activator (tPA)
antigen in patients at increased risk for MI8 or car-
diovascular death,9 further implicating disorders of
the endogenous fibrinolytic system in the thrombot-
ic complications of this multisystemic disease.
The relationship between host coagulation
dynamics and other clinical syndromes associated
with atherosclerosis, such as intermittent claudica-
tion in patients with peripheral arterial disease
(PAD,) has been studied to a lesser degree.
Increased levels of fibrinogen10,11 and D-dimer12,13
(suggesting increased fibrin turnover) and elevated
levels of prothrombin fragment 1 + 2 and thrombin-
antithrombin III complexes13 (suggesting ongoing
thrombin formation) have been reported in patients
with claudication. Increased PAI-1 activity12,14,15
has also been reported, suggesting an associated
impairment of endogenous fibrinolysis. Overall,
these findings suggest that a relative hypercoagula-
ble state may exist in patients with PAD that is in
part caused by reduced endogenous fibrinolytic
activity.
In vivo fibrinolytic activity is best characterized
by the direct assay of the biologic activities of tPA
and PAI-1. Tissue plasminogen activator (tPA)
cleaves the pro-enzyme plasminogen to its active
form, plasmin, which lyses fibrin clots. The fibri-
nolytic activity of tPA is blocked by PAI-1, its
inhibitor, through the formation of an enzymatical-
ly inactive tPA/PAI-1 complex. The hypothesis of
this study was that progressively more severe inter-
mittent claudication is associated with progressively
more impaired endogenous fibrinolytic activity.
Endogenous fibrinolytic activity was determined by
direct measurements of serum levels of tPA antigen,
tPA activity, and PAI-1 activity. These were com-
pared with similar measurements in age-matched
control patients without PAD.
PATIENTS AND METHODS
The study group consisted of 80 men with a
mean age of 69 years. This included 69 patients
enrolled in a multidisciplinary PAD program to
study claudication who were separated into two
groups, one with mild claudication (MC) and one
with severe claudication (SC), as later defined.
Eleven age-matched, normal male subjects without
evidence of PAD, hypertension, coronary artery dis-
ease, hyperlipidemia, or diabetes mellitus served as
controls. Diabetes mellitus was diagnosed by oral
glucose tolerance test. The presence of coronary
artery disease was determined by history of MI, con-
gestive heart failure, or angina, and by abnormal
results on electrocardiogram or graded treadmill
testing. Table I lists the prevalence of these risk fac-
tors, which were similar for both groups with PAD. 
All patients had lower extremity arterial perfu-
sion at rest determined by measurement of continu-
ous-wave Doppler-derived ankle systolic pressures
and calculation of the ankle:brachial index (ABI).
Thereafter, patients with claudication were further
categorized with the following technique:
Claudication was quantitated in study patients by
using a 6-minute walk during which pain-free walk-
ing time and distance were measured. The 6-minute
walk test has been found to be more useful for
assessment of overall functional limitations in
patients with PAD than treadmill testing, because it
is more familiar to the patient and is performed at a
lower intensity that is more representative of normal
daily activities.16 The technique involves placing two
cones 100 feet apart in a marked corridor. Walking
is performed in an overground fashion and timed by
a trained exercise technician with the aid of a stop-
watch. Patients are instructed to walk as many laps
around the cones as possible, and to inform the
technician when the onset of claudication occurs.
The technician records the time and distance to
onset of claudication. Patients are permitted to dis-
continue walking during the test if claudication
becomes intolerable but are instructed to resume
walking as soon as they can. Walking distances are
then converted from feet to meters. Mild claudica-
tion (MC) was defined using the standard criterion
of a pain-free walking distance ‡ 200 m, and severe
claudication (SC) as a pain-free walking distance
<200 m.17 This test has been validated, with a relia-
bility value of 0.90 and a coefficient of variation of
10.4%.16 There were 18 patients with MC and 51
patients with SC in the study group.
Endogenous fibrinolytic activity was quantified
in all patients by measurements of serum tPA anti-
gen, tPA activity, and PAI-1 activity. Samples were
collected using antecubital venipuncture without
tourniquet-induced venostasis at the same time of
day, to eliminate the known diurnal variations in tPA
and PAI-1.18 Blood for measurement of tPA antigen
and activity was collected into 130 mmol/L sodium
citrate anticoagulant (9:1 volume). For measure-
ment of tPA activity, the sample was immediately
acidified by addition of 0.5 mmol/L sodium acetate,
pH 4.2 (2:1 volume), to prevent ongoing in vitro
inactivation of tPA by complex formation with PAI-
1.19 For measurement of PAI-1 activity, samples
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were collected into modified Files solution (1 ml
acid citrate dextrose solution, 80 L acetylsalicylic
acid solution, 10 L prostaglandin E1) to minimize in
vitro platelet activation (final dilution 1:5).20
Samples were maintained at 4° C until centrifuga-
tion at 10,000 · g for 20 minutes. Platelet-poor
plasma was stored at -80° C until assays were per-
formed. The antigen level of tPA was measured 
with an enzyme-linked immunoadsorbent assay
(ELISA).20 Activity levels of tPA and PAI-1 were
assayed by using an amidolytic method.21 All assays
were performed in duplicate, and interassay variabil-
ity was determined to be <5%. Tissue plasminogen
activator antigen level was expressed in nanograms
per milliliter (ng/ml), and its activity was expressed
in international units (IU/ml) assessed against the
Second International Standard for tPA from the
National Institute for Biological Standards and
Control.22 PAI-1 activity was expressed in arbitrary
units (AU/ml); one arbitrary unit of inhibitor is
defined as the amount that inhibits one internation-
al unit of tPA/ml of plasma.23
Measurements of tPA and PAI-1 levels were
combined for all patients in each group and were
expressed as mean ± SEM for comparison. Changes
among groups were compared with an analysis of
variance, and a p-value of <0.05 was used to deter-
mine statistical significance. Measurements of tPA
and PAI-1 were compared with pain-free walking
times in patients with claudication by using linear
regression analysis. This protocol was approved by
the Institutional Review Board of the University of
Maryland, and informed consent was obtained from
all subjects before their participation. 
RESULTS
Ankle-brachial index. The mean ABI was 1.21
± 0.04 in the normal subjects. The ABIs were sig-
nificantly reduced in the two groups with PAD
(MC, mean ABI = 0.65 ± 0.04; SC, mean ABI =
0.58 ± 0.03) compared with the normal group (p
<0.05), but there was no significant differences in
the resting ABIs of patients with MC compared with
those with SC (Table I).
PAI-1 activity. The PAI-1 activity levels for all
patient groups are listed in Table II. Normal subjects
had a mean serum PAI-1 activity level of 12.4 ± 1.7
AU/ml. Serum PAI-1 levels were significantly
increased in both groups with PAD. The mean PAI-
1 level in patients with MC was 21.1 ± 2.1 IU/ml
(p = 0.01 compared with normal patients) and was
20.2 ± 1.0 IU/ml in patients with SC (p = 0.02).
Overall, however, there was no statistically signifi-
cant difference between the two patient groups with
worsening degrees of claudication.
tPA antigen. The mean serum tPA antigen
level was 7.8 ± 0.6 ng/ml in the normal subjects.
In patients with MC, the tPA antigen level was 8.2
± 0.8 ng/ml (p = 0.27 compared with controls)
and patients with SC had a mean tPA antigen level
of 11.4 ± 0.6 ng/ml (p = 0.001, Table II).
Although the tPA antigen levels in the patients
with MC were not distinguishable statistically from
the normal subjects, the patients with SC did have
levels that were significantly elevated relative to
both the control subjects and those with MC.
Analysis of individual tPA antigen levels in patients
with claudication revealed a significant inverse cor-
relation between tPA antigen and pain-free walking
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Table I. Patient characteristics
Normal Mild claudication Severe claudication
Age (years) 69.5 ± 1.5# 68.6 ± 1.5# 68.4 ± 0.8#
Race (%)
White 100 67 53
Black 0 33 47
Tobacco use (%)
Never 36.4 5.6 2.0
Former 63.6 50.0 52.9
Current 0 44.4 45.1
Hypertension (%) 0 84 81
Diabetes mellitus (%) 0 49 55
Hyperlipidemia (%) 0 34 28
Coronary artery disease (%) 0 86 79
ABI 1.21 ± 0.04# 0.65 ± 0.04†* 0.58 ± 0.03†*
Pain-free walking time (seconds) 234 ± 54.3† 109.5 ± 44.0†
*p-value significant at p < 0.05 relative to normal control group.
†Values mean ± SEM.
time during the 6-minute walk test (Fig. 1).
Higher tPA antigen levels in study patients with
claudication were associated with significantly
shorter pain-free walking times (R value -0.395,
p = 0.001).
tPA activity. Table II lists the tPA activity levels
for all groups in the study. Mean tPA activity was
1.74 ± 0.25 IU/ml in the normal subjects. Patients
with mild claudication had a lower mean tPA activi-
ty level of 1.48 ± 0.21 IU/ml, but this difference
was not statistically significant (p = 0.07) compared
with the control subjects. The patients with severe
claudication had a mean tPA activity level of 1.32 ±
0.11 IU/ml that was significantly reduced com-
pared with both the normal controls and the group
with mild claudication (p = 0.01).
DISCUSSION
The progression of atherosclerosis is conceptual-
ized as a gradual obliterative process that leads to a
progressive narrowing of the arterial lumen with a
subsequent reduction in blood flow. It is now rec-
ognized that worsening atherosclerosis, particularly
sudden worsening, is most often caused by acute
thrombosis superimposed on the preexistent plaque
lesion. Acute coronary thrombosis has been identi-
fied as a major precipitating event in acute MI and
sudden cardiac death,24-26 and thrombotic stroke is
well recognized. Acute thrombosis may be precipi-
tated by activation of intrinsic procoagulant factors
or may result from a failure of the endogenous fibri-
nolytic system that leads to decreased removal of
pathologic fibrin deposits.27 In addition, incorpora-
tion of fibrin into the vessel wall may play a role in
new plaque development or contribute to growth of
established plaque by stimulation of smooth muscle
cell proliferation.28
Evidence of impairment of the endogenous fibri-
nolytic system in patients with severe atherosclerosis
has been well documented.1,3,7-9,12,14,15,26-29
Reduced fibrinolytic activity has been most often
characterized by significantly elevated PAI-1 levels in
patients with complication of atherosclerosis such as
unstable angina, acute myocardial infarction, or
stroke,3,9,27,28 although higher PAI-1 activity has
not necessarily been found to correlate with severity
of disease.27,28 Increased PAI-1 levels have also been
associated with symptomatic lower extremity arteri-
al occlusive disease. Johansson et al.15 reported sig-
nificantly higher PAI-1 activity levels in patients with
claudication compared with age-matched controls.
Cortellaro et al.12 did not observe significantly high-
er PAI-1 levels in patients with limb atherosclerosis,
but their study compared patients with limb athero-
sclerosis with others with known coronary and
carotid disease. Notably, however, elevated PAI-1
levels were observed in patients who subsequently
suffered thrombotic events. In a later study,
Cortellaro et al.14 assayed fibrinolytic activity in
patients who had suffered thrombotic events com-
pared with measurements in disease-matched con-
trols. They observed significantly higher PAI-1 lev-
els in the patients with peripheral arterial complica-
tions compared with those with cardiac or
cerebrovascular events. In the current study, both
patient groups with PAD had significantly elevated
PAI-1 activity levels compared with normal control
subjects, although similar to the findings for coro-
nary artery disease, there did not appear to be a cor-
relation between severity of disease and PAI-1 activ-
ity, because the activities were not statistically differ-
ent between the groups with mild and severe
claudication.
Impaired endogenous fibrinolytic activity in
patients with atherosclerosis has also been related to
elevated tPA antigen levels. It would appear para-
doxical to imply that reduced fibrinolysis occurs in
the presence of elevated tPA levels, because tPA is
the primary activator of the endogenous fibrinolytic
system. However, assays of serum tPA antigen mea-
sure both the active enzyme and that which is bound
in the inactive tPA/PAI-1 complex. Because tPA
antigen levels mainly represent the tPA/PAI-1 com-
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Fig. 1. Linear regression analysis showing correlation
between tPA antigen (ng/ml) and time of pain-free walk-
ing (seconds).
plex, it has been thought that in the presence of ele-
vated levels of PAI-1, elevated tPA antigen levels will
actually reflect a reduced tPA activity; thus reduced
fibrinolysis and a relatively hypercoagulable state.
This has recently been verified in a study by
Chandler et al. using a two-compartment pharma-
cokinetic model, based on a computer-simulated
human circulatory system.30
Elevated tPA antigen levels have also been asso-
ciated with clinical events as well as progression in
studies of coronary artery disease. Juhan-Vague et
al.27 in a prospective study of 3043 patients with
angina reported an increased incidence of acute MI
and sudden coronary death in patients with higher
tPA antigen levels. Held et al.9 also demonstrated
increased tPA antigen levels in patients with an
increase risk of cardiovascular death in a prospective
study of 631 patients. Gram and Jespersen,29 in a
follow-up study of postinfarction patients, observed
that the high-risk group for recurrences was charac-
terized by higher tPA antigen and lower tPA activi-
ty. Although Cortellaro et al.14 observed no signifi-
cant increase in the tPA antigen level in patients who
suffered atherothrombotic events, these patients
were observed to have a significantly increased tPA
antigen in response to venostasis. The authors spec-
ulated that this may have reflected a compensatory
mechanism to overcome the observed significant
increases in PAI-1 activity noted in the patients in
that study.
In the current study, tPA antigen levels were sig-
nificantly increased in the group with severe claudi-
cation compared with those with mild claudication
and the normal controls. Moreover, there was a sig-
nificant inverse correlation between tPA antigen lev-
els and pain-free walking times in all claudication
patients. Higher tPA antigen levels were associated
with significantly shorter walking times. Further-
more, mean tPA activity levels in patients with severe
claudication were also significantly reduced com-
pared with those with mild claudication and the nor-
mal control subjects. Taken together, the findings of
increased tPA antigen and decreased tPA activity in
the group with severe claudication suggest that the
progression of mild to severe claudication is associ-
ated with progressive impairment of endogenous
fibrinolysis.
Exercise training has been shown to improve fib-
rinolytic profile by decreasing PAI-1 activity and
increasing tPA activity in older healthy adults31 and
in patients who have experienced myocardial infarc-
tion.32 All patients with claudication in this study also
had significant impairment of endogenous fibrinolyt-
ic activity that was enzymatically characterized by sig-
nificantly increased PAI-1 activity. Moreover, patients
with more severe claudication had worsening fibri-
nolytic activity relative to those with mild claudica-
tion and to the control subjects, characterized by
increased tPA antigen and decreased tPA activity.
Although speculative at this time, it is possible that
exercise training in patients with mild claudication
might be beneficial in preventing deterioration of the
fibrinolytic profile and in retarding progression of
disease to more severe levels. Clearly, this is an appro-
priate direction for future research efforts.
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